aTYR PHARMA (ATYR) Current Deferred Revenue (2014 - 2020)
aTYR PHARMA's (ATYR) quarterly Current Deferred Revenue came in at $53000.0 in Q3 2020, down 84.94% on a YoY basis from $352000.0 in Q4 2019, and down 73.63% quarter-over-quarter from $201000.0 in Q2 2020.
Powered by 
Analysis
aTYR PHARMA (ATYR) Current Deferred Revenue (2014 - 2020) Analysis & Trends
aTYR PHARMA (ATYR) has reported Current Deferred Revenue for 6 consecutive years, with $53000.0 the latest figure, recorded in Q3 2020.
- For the quarter ending Q3 2020, Current Deferred Revenue fell 84.94% year-over-year to $53000.0; the trailing twelve-month figure through Sep 2020 stood at $53000.0 (down 84.94% YoY), and the FY2019 full-year result was $208000.0, changed N/A from the prior year.
- Current Deferred Revenue declined to $53000.0 in Q3 2020 per ATYR's latest filing, from $201000.0 in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $630000.0 in Q1 2019 and bottomed at $49000.0 in Q1 2017.
- Historically, Current Deferred Revenue has averaged $260333.3 across 4 years, with a median of $209500.0 in 2016.
- The sharpest annual moves came in 2016 and 2020: Current Deferred Revenue grew 6.67% in 2016, then slumped 84.94% in 2020.
- Over 4 years, Current Deferred Revenue stood at $130000.0 in 2016, then sank by 62.31% to $49000.0 in 2017, then soared by 324.49% to $208000.0 in 2019, then tumbled by 74.52% to $53000.0 in 2020.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $53000.0, $201000.0, and $143000.0 for Q3 2020, Q2 2020, and Q1 2020 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | aTYR PHARMA | 35.31 Mn | -22.30 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | 53,000.00 |
| Jun 30, 2020 | 201,000.00 |
| Mar 31, 2020 | 143,000.00 |
| Dec 31, 2019 | 208,000.00 |
| Sep 30, 2019 | 352,000.00 |
| Jun 30, 2019 | 536,000.00 |
| Mar 31, 2019 | 630,000.00 |
| Mar 31, 2017 | 49,000.00 |
| Dec 31, 2016 | 130,000.00 |
| Sep 30, 2016 | 211,000.00 |
| Jun 30, 2016 | 291,000.00 |
| Mar 31, 2016 | 320,000.00 |
| Dec 31, 2015 | 315,000.00 |
| Sep 30, 2015 | 310,000.00 |
| Jun 30, 2015 | 305,000.00 |
| Mar 31, 2015 | 300,000.00 |
| Dec 31, 2014 | 295,000.00 |